Calando Pharmaceuticals, new Arrowhead Subsidiary, to Commercialize Therapeutic RNAi Delivery Technologies

Feb 22, 2005

NEW YORK, Feb. 22 (GenomeWeb News) - Arrowhead Research has formed a new subsidiary, Calando Pharmaceuticals, which plans to commercialize technologies for the therapeutic use of RNA interference, the Pasadena, Calif.-based company said today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Main menu